产品
  • 产品
  • 供应商
  • 采购
  • 资讯
  • 会展
猜你想搜
首页 制药产品大全 生物制品 生化原料药 GLP-1(7-37)

GLP-1(7-37)

2026-10-31

产品详情

GLP-1(7-37)
肽类
中国药典,美国药典,欧洲药典,企业标准
药用级
peptide hormone/=incretin/=decrease blood sugar levels/=type 2 diabetes/=DPP-4
否
As per requirement
As per requirement
10克
capacity >10,000 grams
2weeks-4weeks
中国,北美洲,亚洲,中东
无

产品描述

Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem upon food consumption. The initial product GLP-1 (1–37) is susceptible to amidation and proteolytic cleavage, which gives rise to the two truncated and equipotent biologically active forms, GLP-1 (7–36) amide and GLP-1 (7–37). Active GLP-1 protein secondary structure includes two α-helices from amino acid position 13–20 and 24–35 separated by a linker region.

Alongside glucose-dependent insulinotropic peptide (GIP), GLP-1 is an incretin; thus, it has the ability to decrease blood sugar levels in a glucose-dependent manner by enhancing the secretion of insulin. Beside the insulinotropic effects, GLP-1 has been associated with numerous regulatory and protective effects. Unlike GIP, the action of GLP-1 is preserved in patients with type 2 diabetes. Glucagon-like peptide-1 receptor agonists gained approval as drugs to treat diabetes and obesity starting in the 2000s.

Endogenous GLP-1 is rapidly degraded primarily by dipeptidyl peptidase-4 (DPP-4), as well as neutral endopeptidase 24.11 (NEP 24.11) and renal clearance, resulting in a half-life of approximately 2 minutes. Consequently, only 10–15% of GLP-1 reaches circulation intact, leading to fasting plasma levels of only 0–15 pmol/L. To overcome this, GLP-1 receptor agonists and DPP-4 inhibitors have been developed to increase GLP-1 activity. As opposed to common treatment agents such as insulin and sulphonylureas, GLP-1-based treatment has been associated with weight loss and a lower risk of hypoglycemia, two important considerations for patients with type 2 diabetes.


苏州法默赛科技有限公司
访问店铺
注册资本
公司地址
联系人

公司简介

以“关爱生命、健康至上、可负担的API”为使命,我们希望与您携手合作,实现共赢,共同促进健康生活。 我司主要产品包括 司美格鲁肽、替尔泊肽、利拉鲁肽、依替巴肽、加尼瑞克、醋酸格拉替雷、特利加压素乙酸盐、奥曲肽乙酸盐、催产素乙酸盐、去氨加压素、亮丙瑞林、醋酸西曲瑞克、醋酸卡贝缩宫素、醋酸阿托西班、利那洛肽。
业务类型:
成立日期:
年营业额:
主营产品类别: